Regeneron Pharmaceuticals (REGN) has reported a series of announcements showing an overall rise in investor confidence despite a recent price drop. UBS Group gave REGN a new price target of $660, hinting at expected growth, with market analysts predicting a potential rise due to strong Q3 earnings. Various asset management and investment groups, such as Harvest Portfolios Group and Resona Asset Management, have increased their stakes in the company, reflecting growing confidence in its prospects. REGN's partnership with ModeX and its recent Phase 3 trial successes, especially the one with Garetosmab for a rare disease, are anticipated to shift its growth trajectory positively. Critical drug approvals indicate the company's strong pipeline, with the FDA extending the review deadlines for two of REGN’s submissions. Several entities, including Wells Fargo and AMG National Trust Bank, have emphasized a positive outlook for REGN. However, some display caution due to marginal dips and recent market performance. Overall, the consensus points to the company's resilience and promises strong growth potential.
Regeneron Pharmaceuticals REGN News Analytics from Wed, 11 Jun 2025 07:00:00 GMT to Sat, 08 Nov 2025 18:52:48 GMT -
Rating 7
- Innovation 8
- Information 7
- Rumor -3
